Hospital Acquired Infections Therapeutics Market – By Drug Type, By Route of Administration, By Infection Type, & Global Forecast, 2024 – 2032

Major players in the industry include Abbott, AbbVie, Allergan Plc, Eugia Pharma, Bayer, DAIICHI SANKYO COMPANY, F. Hoffmann-La Roche, Glenmark Pharmaceuticals, GSK, and Hikma Pharmaceuticals.

North America market generated USD 4.7 billion in 2023, driven by its high incidence of HAIs and a well-established healthcare infrastructure.

Antibacterial drugs accounted for the highest revenue of USD 9.2 billion in 2023, driven by the increasing prevalence of antibiotic-resistant bacteria in healthcare settings.

The global market size for hospital-acquired infections therapeutics was valued at approximately USD 12.6 billion in 2023 and is expected to reach around USD 16.4 billion by 2032, driven by a CAGR of 3.2% from 2024 to 2032.